BioXcel Therapeutics achieved targeted exposures of BXCL501 for neuropsychiatric diseases
BioXcel Therapeutics announced positive top line data from its Phase 1 pharmacokinetic (bioavailability) and safety study of BXCL501, a proprietary sublingual thin-film formulation of dexmedetomidine (Dex), for acute treatment of agitation across multiple neuropsychiatric indications. May 20, 2019